Teva Pharmaceutical Industries Ltd. $TEVA Position Boosted by Bessemer Group Inc.

Bessemer Group Inc. grew its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 1.6% during the first quarter, Holdings Channel.com reports. The firm owned 4,350,483 shares of the company’s stock after buying an additional 70,058 shares during the quarter. Bessemer Group Inc.’s holdings in Teva Pharmaceutical Industries were worth $131,036,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of TEVA. Aster Capital Management DIFC Ltd acquired a new stake in Teva Pharmaceutical Industries in the fourth quarter worth approximately $25,000. Allworth Financial LP raised its stake in shares of Teva Pharmaceutical Industries by 53.8% in the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after buying an additional 329 shares in the last quarter. Grove Bank & Trust raised its stake in shares of Teva Pharmaceutical Industries by 300.0% in the 4th quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock worth $31,000 after buying an additional 750 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 51.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after buying an additional 345 shares during the period. Finally, Caitong International Asset Management Co. Ltd lifted its holdings in shares of Teva Pharmaceutical Industries by 567.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,334 shares of the company’s stock valued at $42,000 after buying an additional 1,134 shares during the period. 54.05% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Barclays raised their target price on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Truist Financial lifted their price target on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Wall Street Zen cut Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Monday, April 20th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $41.78.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Richard Daniell sold 30,000 shares of the business’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $35.40, for a total transaction of $1,062,000.00. Following the completion of the transaction, the executive vice president owned 55,755 shares of the company’s stock, valued at $1,973,727. The trade was a 34.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Amir Weiss sold 10,679 shares of the stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $36.00, for a total value of $384,444.00. Following the sale, the chief accounting officer owned 20,016 shares of the company’s stock, valued at approximately $720,576. The trade was a 34.79% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 465,931 shares of company stock valued at $16,332,989 in the last three months. Company insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA opened at $32.00 on Friday. The business’s 50-day moving average is $33.76 and its 200-day moving average is $32.69. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. The company has a market capitalization of $36.79 billion, a price-to-earnings ratio of 24.06, a P/E/G ratio of 3.40 and a beta of 0.86. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $14.99 and a fifty-two week high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The firm had revenue of $3.98 billion for the quarter. Equities research analysts expect that Teva Pharmaceutical Industries Ltd. will post 1.99 EPS for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.